Recent studies have converged on the convergence of GLP|GIP|GCGR activator therapies and DA neurotransmission. While GLP stimulators are widely employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically mediated by dopamine pathways, are attracting substantial attention. This paper provides a summa